Revvity, Inc., today reported financial results for the first quarter ended April 2, 2023.
Cue Health Inc., a healthcare technology company, today reported financial results for the first quarter 2023.
Siemens Healthineers AG today announces its results for the second quarter, ending March 31, of fiscal year 2023.
Invitae, a leading medical genetics company, announced financial and operating results for the first quarter ended March 31, 2023.
DiaSorin said that its first quarter 2023 revenues fell 19 percent year over year on a sharp decline in COVID-19 testing, partially offset by growth in its non-COVID-19-related diagnostics revenues.
Veracyte, Inc. today announced financial results for the first quarter ended March 31, 2023.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023.
QIAGEN announced results for the first quarter of 2023.
On April 27, Mindray released its annual report, showing that in 2022, it achieved revenue of 30.366 billion CNY, up 20.17% year-on-year, net profit attributable to shareholders of the listed company was 9.607 billion CNY, up 20.07% year-on-year; net cash flow from operating activities was 12.141 billion CNY, up 34.92% year-on-year, and basic earnings per share was 7.94 CNY.
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2023.
✔ All (240)
✔ Press release (0)
✔ Industry news (240)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.